The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Adjuvant enzalutamide for the treatment of early-stage androgen receptor-positive (AR+) TNBC.
 
Tiffany A. Traina
Consulting or Advisory Role - Aduro Biotech; Advaxis; Astellas Pharma; AstraZeneca; Athenex; Bristol-Myers Squibb; Celgene; Genentech/Roche; Genomic Health; Halozyme; Halozyme; Halozyme; Halozyme; Halozyme; Innocrin Pharma; Medivation; Merck; Pfizer; Puma Biotechnology; Samsung
Speakers' Bureau - Roche/Genentech
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Genentech/Roche (Inst); Immunomedics (Inst); Innocrin Pharma (Inst); Novartis (Inst); Pfizer (Inst)
 
Leigh Ann Boyle
Research Funding - Astellas Oncology (Inst)
 
Artavazd Arumov
Research Funding - Astellas Oncology (Inst)
 
Sujata Patil
No Relationships to Disclose
 
Marcia Edelweiss
No Relationships to Disclose
 
Patricia Anne DeFusco
No Relationships to Disclose
 
Mila Gorsky
No Relationships to Disclose
 
Nicholas E. Lamparella
No Relationships to Disclose
 
Shanu Modi
Speakers' Bureau - Genentech
Research Funding - Daiichi Sankyo; Novartis; Roche/Genentech; Seagen; Synta
 
Rachel Ann Sanford
No Relationships to Disclose
 
Ayca Gucalp
Consulting or Advisory Role - Innocrin Pharma; Pfizer
Research Funding - Innocrin Pharma (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Innocrin Pharma